NAPANEE, ON, June 5, 2019 /CNW/ - VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) ("VIVO" or the "Company"), a leading provider of premium cannabis products and services for the medical and adult-use markets and licensed producer of cannabis under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited and ABcann Medicinals Inc., and its medical cannabis clinic network operated by Harvest Medicine Inc., today announced the results of its annual general and special meeting of shareholders held on June 4, 2019 (the "Meeting").

The Company put forward the following resolutions to be voted on by shareholders at the Meeting, all of which were approved: (i) to re-appoint MNP LLP as auditor of the Company for the 2019 fiscal year; (ii) fixing the number of directors of the Company at six; (iii) the election of directors; and (iv) the ratification of the Company's 2017 Stock Option Plan.

A total of 122,552,741 of the 294,800,314 common shares of the Company that were outstanding as at the record date were voted at the Meeting, representing 41.6% of such shares.

Each of the directors elected at the Meeting, being Paul Lucas, Barry Fishman, John Easson, Richard Fitzgerald, Daniel Laflamme and Daryl Kramp, will hold office until the next annual meeting of the Company or until their earlier resignation or removal. Aaron Keay did not stand for re-election at the Meeting and ceased to be a director of the Company effective June 4, 2019.

Following the Meeting, the Board determined to grant an aggregate of 575,000 stock options to certain directors and employees of the Company, each of which is exercisable into one common share of the Company at an exercise price of $0.64 share, being the closing price on June 4, 2019, until June 4, 2024. Of these, an aggregate of 475,000 options were granted to independent directors of the Company in partial satisfaction of their annual director fees, and 100,000 options were granted to an employee. The options granted will vest in stages in accordance with their respective terms. The shares issuable on exercise of the stock options will be subject to a TSX Venture Exchange hold period of four months and one day from the date of grant of the options.

About VIVO Cannabis™

VIVO, based in Napanee, Ontario, is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities with proprietary plant-growing technology at its Canna Farms facility in Hope, B.C., and at its Vanluven facility in Napanee, Ontario. VIVO has a collection of premium brands targeting unique customer segments, including Beacon Medical™, Fireside™, Canna Farms™ and Lumina™. The Company is significantly expanding its production capacity and distribution channels; growing its domestic medical cannabis platform, including Harvest Medicine, its patient-centric, highly scalable network of specialty medical cannabis clinics and services; promoting production and cultivation innovation and pursuing partnership and product development opportunities; and actively focusing on growth in select international markets, including Germany and Australia. VIVO has a healthy balance sheet and is well-positioned to accelerate its growth in Canada and internationally. For more information visit: www.vivocannabis.com

ON BEHALF OF THE BOARD OF DIRECTORS

Barry Fishman

CEO and Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE VIVO Cannabis Inc.

For further information: VIVO Investor Relations, Craig MacPhail, +1.416-848-9839, [email protected], NATIONAL Capital Markets; Michael Bumby, Chief Financial Officer, [email protected], VIVO Cannabis Inc.

Related Links

https://www.vivocannabis.com/

